Eloxx Pharmaceuticals, Inc. ELOX
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Eloxx Pharmaceuticals, Inc. (ELOX) is a healthcare company listed in the US with a market value of about $53M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -724%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 91% below the current price.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals is listed in the US and classified in biotechnology: biological products (no diagnostic substances). It was profitable in 0 of the last 10 years in our data. Its share count rose by 470% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- ROE above 15%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6M | $0 | — | — | — | — | — | — | — |
| Net income | -$6M | -$3M | -$17M | -$36M | -$67M | -$35M | -$51M | -$47M | -$21M | -$10M |
| Free cash flow | — | — | — | -$32M | -$35M | — | -$39M | -$32M | -$16M | -$9M |
| EPS (diluted) | $-0.49 | $-0.84 | $-6.63 | $-16.65 | $-38.15 | $-0.86 | $-1.34 | $-1.45 | $-4.75 | $-2.60 |
| Net margin | — | -49.4% | — | — | — | — | — | — | — | — |
| ROIC | — | — | — | -1263.5% | -184.2% | -150.2% | -97.3% | -87.6% | -75.4% | -1274.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Eloxx Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 91% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Eloxx Pharmaceuticals pay a dividend?
Not currently.
Is Eloxx Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Eloxx Pharmaceuticals scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.